I was diagnosed with Stage 3 colon cancer at 33 — this was the symptom I initially dismissed
'Hands down, colon cancer awareness,' Ramsey, 39, told The Post. 'At the time, I was a four-year survivor, and I was like, 'I just want to be able to help as many people as I can.''
With March being Colorectal Cancer Awareness Month, Ramsey is also working with the Colorectal Cancer Alliance to share her story. She hopes to encourage people to get screened for the disease — her journey has already revealed that colon cancer is more common in her family than she thought.
Friends and family were stunned when Ramsey learned in 2019 that she had Stage 3 colon cancer at the age of 33. Colorectal cancer typically affects people over 50, but there's been a concerning uptick in diagnoses among younger adults.
Ramsey was not as surprised by the news. As an operating room nurse, she knew the importance of listening to her body.
'In my spirit, I just knew something wasn't right,' Ramsey, who lives in Canton, Mississippi, recalled.
Ramsey initially noticed blood in her stool after giving birth to son Ashton in 2011. She dismissed it as hemorrhoids.
The bleeding became more frequent in 2019 and included mucus, so she underwent a colonoscopy. The exam revealed that she had a 5-centimeter polyp in her sigmoid colon, the section of the colon that connects to the rectum.
Shortly thereafter, doctors removed 3 feet of her colon and 13 lymph nodes. Because the cancer had spread to three of these lymph nodes, Ramsey was diagnosed with Stage 3 colon cancer.
She begged her family members to get screened. Having first-degree relatives (parents, siblings or children) with colon cancer greatly increases the risk of developing the disease.
'We found out that we do, in fact, have a significant family history,' Ramsey said.
Her dad had his entire colon removed upon the discovery of several precancerous polyps, her brother is set to have a portion of his colon cut out, and her aunt lost part of her colon after a tumor was found.
Her family addressing their colon cancer is not the only positive outcome of this ordeal.
Ten days after surgery, for her birthday, Ramsey attended a New Orleans Saints game with her then-boyfriend, Mickee.
As time on the clock expired, Wil Lutz kicked a 33-yard field goal for the Saints to beat the Carolina Panthers 34-31. Ramsey was a bit distracted trying to make sure no one accidentally touched her stomach as they celebrated — because it still had staples — so she didn't notice Mickee beginning to propose.
'He said, 'I just want you to know I'm not proposing to you because you're sick. I've been planning this for a long time,'' Ramsey said. 'He was like, 'It just threw a little hiccup in our plan.''
The couple ended up on the jumbotron, and Saints linebacker Demario Davis retweeted footage of the special moment.
Ramsey started chemotherapy weeks later, in January 2020. As if that wasn't stressful enough, the COVID-19 pandemic hit and Mickee was deployed to the Bronx Zoo to help emergency personnel with ambulance services.
The couple wed in June, two weeks after Mickee returned to Mississippi.
On Father's Day in 2020, Ramsey learned she was pregnant.
Throughout her cancer journey, Ramsey had persistent dreams of having another boy, with 'Luke' or 'Lucas' in his name. They welcomed Emree Lucas-Ray in February 2021 after Ramsey had a taxing bout of COVID.
'He's absolutely perfect in every way, and his name actually means strong, shining light,' Ramsey said. 'It was just kind of like a breath of fresh air after the whole colon cancer thing.'
Ramsey has been cancer-free for five years as of this month. In April, she passes her crown to a new Mrs. Mississippi Plus America, a title celebrating plus-sized wives in the state.
Ramsey has been using that platform and social media to remind people to schedule colonoscopies.
Colorectal cancer has a 91% survival rate when caught early, yet one-third of eligible adults aren't getting screened. A recent study from the Colorectal Cancer Alliance found that most Americans would rather do pretty much anything else.
Adults at average risk are encouraged to begin screening at 45, while those with a family history like Ramsey likely need to get examined earlier and more often.
'I just want to spread awareness,' she said, 'to get people involved, to get a screening and to listen to their bodies, because if something doesn't seem right, more than likely it's not.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
5 minutes ago
- Indianapolis Star
A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials
SHELTON, CONNECTICUT / ACCESS Newswire NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the 'Company'), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, reports that its broad-spectrum antiviral drug NV-387 could help reduce resurgence of metastatic cancer caused by awakening of 'sleeping' cancer cells due to viral infections. NV-387 has successfully completed a Phase I clinical trial and is being advanced into Phase II clinical trials. Recently, increase in inflammation, and particularly the cytokine IL-6, caused by viral infections has been found to be linked to an increased risk of resurgence of metastatic cancer, in a study of COVID-19 (SARS-CoV-2 infection) and breast cancer, as well as Influenza virus infections and cancer [1] . This study has further substantiated that viral infections can lead to resurgence of metastatic cancers by re-activating 'sleeping' cancer cells. 'NV-387 is a remarkable antiviral drug, in that it not only attacks the virus, but also reduces inflammation, calming the human immune system so that untoward effects do not take place,' said Anil R. Diwan, Ph.D., President and Chairman of the Company, adding, 'We have found that NV-387 treatment reduces inflammation markers, particularly, IL-6, thereby protecting lungs. This reduction in inflammation and cyto-protective effect of NV-387 would also help minimize the risk of reawakening cancer, based on these reported studies.' Thus NV-387 treatment could have a strong impact in the treatment of cancer patients in remission who suffer from a viral infection that could lead to the cancer returning with metastasis to multiple sites in the body. COVID-19 has become endemic globally, with generally two waves every year. The summer surge is already occurring in the USA, with approximately 4,000 hospitalizations per week in the week ending July 26 at the beginning of the surge, fueled by ever-changing variants [2] . Influenza virus is a well-known endemic virus that causes pandemics globally. RSV is an endemic virus that causes particularly severe diseases in infants and children as well as adults. Measles virus causes 'immune system amnesia' and is increasing globally. NV-387 is the only antiviral drug that has been uniquely found to be effective in the treatment of lethal lung viral infections caused by all of these viruses in animal model studies that are predictive of human clinical effectiveness. This clearly demonstrates the unmet medical need for NV-387, a broad-spectrum antiviral that the viruses cannot escape even as new variants are created. In contrast, antibodies and vaccines readily fail with new variants arising, as is now well known. NV-387 treatment has been found to reduce the level of IL-6 in lethal viral infections causing lung diseases in animal models. Excellent protection of lungs was found to occur in NV-387-treated animals but not in ribavirin treated animals in a lethal RSV infection study. Strong protection of lungs was found to occur in NV-387-treated animals in a lethal lung-infection of Influenza A/H3N2 study. In this Influenza study, the approved drugs Tamiflu (oseltamivir), Rapivab (peramivib), and Xofluza (baloxavir) failed to protect the lungs of animals to any appreciable extent, indicating the superiority and clinical viability of NV-387. The Company further investigated the extra-ordinary effect of NV-387 on protection of lungs in lethal viral infections. Reduction in inflammatory cytokines, particularly IL-6, was found to occur to an appreciable extent in NV-387 treated animals. ABOUT NANOVIRICIDES NanoViricides, Inc. (the 'Company') ( is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading 'Risk Factors' and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. The phrases 'safety', 'effectiveness' and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA. FDA refers to US Food and Drug Administration. IND application refers to 'Investigational New Drug' application. cGMP refers to current Good Manufacturing Practices. CMC refers to 'Chemistry, Manufacture, and Controls'. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for 'Active Pharmaceutical Ingredient'. WHO is the World Health Organization. R&D refers to Research and Development. Public Relations Contact: ir@ [1] Publication: 'Respiratory viral infections awaken metastatic breast cancer cells in lungs', Chia et al, J DeGregori group, [2] Centers for Disease Control and Prevention. COVID Data Tracker. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2025, August 18. SOURCE: NanoViricides, Inc. View the original press release on ACCESS Newswire The post A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials appeared first on DA80 Hub.
Yahoo
6 minutes ago
- Yahoo
New Covid wave warning as cases in hospital patients soar by 31% in a fortnight
Covid cases in hospital patients have jumped by almost a third in a fortnight - sparking concerns of a new Covid wave. The number of hospital patients with respiratory symptoms testing positive for the virus has increased from 5.8 per cent on 26 July to 7.6 per cent on 10 August, according to the UK Health Security Agency (UKHSA). That marks an increase of 31 per cent in just 15 days. This percentage is known as the positivity rate and it is much higher among hospital patients with symptoms than the general public. The rise in cases in hospitals could be an indication the country is facing a new wave of infections, with epidemiologists suggesting soaring cases could be a cause for concern. 'This rise in cases reinforces the fact that the virus is still circulating and is capable of spreading,' Professor Lawrence Young, a virologist at Warwick University told The Independent. He added: 'A particular concern is the impact on infection levels as people return to work and school after the holiday season and the effect of cooler weather. This coupled with new virus variants and restricted access to free vaccines over the Autumn period is worrying.' But experts stress it is difficult to get an accurate picture as people no longer routinely test for the virus. Infectious disease expert Professor Paul Hunter, at University of East Anglia, explained that infection numbers have been drifting up and down for most of the year and he expects cases to rise as we approach the end of the year. 'We will see further increases but against a continuing declining general trend in hospitalisation and deaths. As to how many infections are occurring in the community. I have no idea as we only really test people in hospitals now,' Professor Hunter told the Independent. 'As to how many infections are occurring in the community, I have no idea as we only really test people in hospital now,' he added. Although this spike of 7.6 per cent is still lower than it was for most of the pandemic, it's much higher than it was in January when it was 2.2 per cent. In July last year, cases hit 16.6 per cent and 14.6 per cent in October last year, according to UKHSA data. The Covid vaccine is usually offered on the NHS in spring and early winter to people who need extra protection from the virus. But this year almost 13 million fewer people will be offered the booster jab. The Government is no longer offering the jab to pensioners aged 65 to 74, nor are they offering it to pregnant women or people with chronic heart disease or liver disease. This autumn the vaccine will be offered to adults over 75, residents in care homes for older adults and those who are immunosuppressed over the age of six months.
Time Magazine
4 hours ago
- Time Magazine
Public Health Workers Criticize RFK Jr. After CDC Shooting
More than 750 public health workers sent a letter to Health Secretary Robert F. Kennedy Jr. on Wednesday, urging him to 'stop spreading inaccurate health information' and guarantee employees' safety, in the wake of a shooting at the headquarters of the Centers for Disease Control and Prevention (CDC) earlier this month. The letter—signed by both named and anonymous current and former staffers at the U.S. Department of Health and Human Services (HHS), CDC, and National Institutes of Health who noted they signed the letter in their 'own personal capacities'—said the attack on the CDC's headquarters in Atlanta on Aug. 8 'was not random.' 'The attack came amid growing mistrust in public institutions, driven by politicized rhetoric that has turned public health professionals from trusted experts into targets of villainization—and now, violence,' public health workers said in the letter, which was also addressed to members of Congress. 'CDC is a public health leader in America's defense against health threats at home and abroad. When a federal health agency is under attack, America's health is under attack. When the federal workforce is not safe, America is not safe.' The public health workers went on to accuse Kennedy, a prominent vaccine skeptic, of being 'complicit in dismantling America's public health infrastructure and endangering the nation's health by repeatedly spreading inaccurate health information.' They cited several statements and actions that Kennedy has made in recent months, pointing to his claim that mRNA vaccines 'fail to protect effectively' against upper respiratory infections such as COVID-19—despite years of research showing that the shots are both safe and effective—and his announcement that HHS would be winding down mRNA vaccine development. They also condemned his decision to remove all the experts from a critical vaccine advisory committee. And they said some of Kennedy's past comments—such as claiming that there is a 'cesspool of corruption at CDC'—were 'sowing public mistrust' in the health agency. The public health workers expressed their wish to honor police officer David Rose, who was killed while responding to the attack on the CDC headquarters in August. HHS said in a statement to TIME that Kennedy 'is standing firmly with CDC employees—both on the ground and across every center—ensuring their safety and well-being remain a top priority.' The agency added that, after the shooting earlier this month, Kennedy traveled to Atlanta and called the CDC 'a shining star' among the world's health agencies. 'For the first time in its 70-year history, the mission of HHS is truly resonating with the American people—driven by President Trump and Secretary Kennedy's bold commitment to Make America Healthy Again,' HHS said. 'Any attempt to conflate widely supported public health reforms with the violence of a suicidal mass shooter is an attempt to politicize a tragedy.' Law enforcement officials said they found evidence that the suspect in the August shooting, who they identified as Patrick Joseph White of Georgia, blamed the COVID-19 vaccine for his health ailments. White was found dead at the scene, and authorities later said that he died of a self-inflicted gunshot wound. CDC Director Susan Monarez noted the dangers posed by misinformation in a staff meeting in the wake of the attack. 'We know that misinformation can be dangerous,' she said, according to NBC News. 'Not only to health, but to those that trust us and those we want to trust. We need to rebuild the trust together.' The day after the shooting, Kennedy expressed his condolences to Rose's family in a post on X. 'We know how shaken our public health colleagues feel today. No one should face violence while working to protect the health of others,' he said. 'We are actively supporting CDC staff on the ground and across the agency. Public health workers show up every day with purpose—even in moments of grief and uncertainty. We honor their service. We stand with them. And we remain united in our mission to protect and improve the health of every American.' Kennedy was one of President Donald Trump's most controversial Cabinet nominees, and faced heated questioning by Senators during his confirmation hearings. He has drawn outrage from the medical establishment in the past for spreading disinformation, including repeating the debunked claim that vaccines cause autism. In their letter, public health workers claimed Kennedy's 'dangerous and deceitful statements and actions have contributed to the harassment and violence experienced by CDC staff.' They implored him to take three steps by Sept. 2 to 'uphold his pledge to safeguard the health of the American public,' including asking him to 'stop spreading inaccurate health information,' particularly regarding vaccines, infectious disease transmission, and the country's public health institutions. They also urged him to affirm the scientific integrity of the CDC and guarantee the safety of HHS employees, such as through emergency procedures and alerts. 'The deliberate destruction of trust in America's public health workforce puts lives at risk,' they wrote in the letter. 'We urge you to act in the best interest of the American people—your friends, your families, and yourselves.'
